CN117731007A - Pumpkin seed protein composition and application thereof - Google Patents

Pumpkin seed protein composition and application thereof Download PDF

Info

Publication number
CN117731007A
CN117731007A CN202211114142.1A CN202211114142A CN117731007A CN 117731007 A CN117731007 A CN 117731007A CN 202211114142 A CN202211114142 A CN 202211114142A CN 117731007 A CN117731007 A CN 117731007A
Authority
CN
China
Prior art keywords
protein
composition
pumpkin seed
subject
intestinal
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202211114142.1A
Other languages
Chinese (zh)
Inventor
江龙
吴婧
廖琪林
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nanjing Niubang Biotechnology Co ltd
Original Assignee
Nanjing Niubang Biotechnology Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nanjing Niubang Biotechnology Co ltd filed Critical Nanjing Niubang Biotechnology Co ltd
Priority to CN202211114142.1A priority Critical patent/CN117731007A/en
Priority to PCT/CN2023/118501 priority patent/WO2024055983A1/en
Publication of CN117731007A publication Critical patent/CN117731007A/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K10/00—Animal feeding-stuffs
    • A23K10/10—Animal feeding-stuffs obtained by microbiological or biochemical processes
    • A23K10/16—Addition of microorganisms or extracts thereof, e.g. single-cell proteins, to feeding-stuff compositions
    • A23K10/18—Addition of microorganisms or extracts thereof, e.g. single-cell proteins, to feeding-stuff compositions of live microorganisms
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K20/00—Accessory food factors for animal feeding-stuffs
    • A23K20/10—Organic substances
    • A23K20/142—Amino acids; Derivatives thereof
    • A23K20/147—Polymeric derivatives, e.g. peptides or proteins
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K20/00—Accessory food factors for animal feeding-stuffs
    • A23K20/10—Organic substances
    • A23K20/174—Vitamins
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
    • A23L2/38—Other non-alcoholic beverages
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/17—Amino acids, peptides or proteins
    • A23L33/185—Vegetable proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/01—Hydrolysed proteins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Polymers & Plastics (AREA)
  • Engineering & Computer Science (AREA)
  • Health & Medical Sciences (AREA)
  • Food Science & Technology (AREA)
  • Nutrition Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Husbandry (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Mycology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Physiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)

Abstract

The invention discloses a pumpkin seed protein or a composition of separated protein, hydrolyzed protein and concentrated protein thereof and application thereof in preparing medicines, nutritional products, health products, foods, beverages and animal feeds for regulating intestinal flora. The pumpkin seed protein or the composition of the isolated protein, the hydrolyzed protein and the concentrated protein thereof can obviously increase the level of the first intestinal microbiota in the subject, and simultaneously reduce the level of escherichia coli in the subject so as to improve the intestinal health, thereby improving the overall health; the invention discovers the new functions and nutrition characteristics of the pumpkin seed protein, improves the added value of pumpkin seed utilization, and expands the application range of the pumpkin seed protein.

Description

Pumpkin seed protein composition and application thereof
Technical Field
The invention belongs to the technical field of health-care foods and dietary supplements, and particularly relates to a pumpkin seed protein or a composition of separated protein, hydrolyzed protein and concentrated protein thereof, and related application of the pumpkin seed protein or the composition in medicines, nutritional supplements, health-care products, foods, beverages and animal feeds.
Background
Studies have shown that human health is not only related to its own genome, but also in a dense and inseparable relationship with environmental microorganisms in the gut. The intestinal flora has a very important role in the human body, and is regarded as a further "hidden organ" of the body, carrying the "second gene" of the body, so that the body is also shaped as a super organism. Intestinal flora regulates intestinal homeostasis through interactions with the host; imbalance in intestinal homeostasis caused by various causes will affect the health of the human body, leading to the development of various diseases.
Lactobacillus acidophilus exists mainly in the small intestine, can release lactic acid, acetic acid and some antibiotics which act on harmful bacteria, and is intestinal probiotics; streptococcus thermophilus is an oxygen-consuming gram-positive bacterium, is a beneficial bacterium existing in human intestinal tracts, and can help lactose intolerant people digest lactose; bifidobacteria are important intestinal beneficial microorganisms, have nutrition, anti-tumor and immunity enhancing effects on human health, play a variety of physiological functions such as biological barrier, gastrointestinal tract function improvement, aging resistance and the like, and are typically represented by bifidobacterium longum, bifidobacterium lactis and the like. Coli is a conditional pathogenic bacterium, belongs to gram-negative bacteria, and can cause gastrointestinal tract infection or urinary tract infection of various local tissues and organs of people and various animals under certain conditions.
The intestinal probiotics can synthesize various vitamins (mainly vitamins K and B), participate in the digestion of foods (such as carbohydrates) to generate lactic acid, promote intestinal peristalsis, inhibit the growth of pathogenic bacteria, decompose harmful substances, activate the immune system, maintain the balance of intestinal flora, and are indispensable to human health. The regulation of intestinal flora and the improvement of intestinal microenvironment can be realized by exogenous supplementing probiotics; the probiotics must be in sufficient quantity to function, and have high requirements on the preparation process, storage conditions, price and the like. Pathogenic bacteria produce pathogenic substances that cause host infection. In order to maintain intestinal health, it is necessary to promote the proliferation of intestinal probiotics and reduce the number of intestinal pathogens.
Pumpkin seeds contain a great amount of nutrient components such as fat, protein, plant sterol, various minerals and the like, and the health care value of the pumpkin seeds is approved worldwide. In recent years, studies have been made on extraction and separation from pumpkin seeds and utilization of pumpkin seed proteins. The development and application of pumpkin seed proteins are mainly focused on the agricultural field, and researches show that antifungal proteins extracted from naked-kernel pumpkin seeds have remarkable growth inhibition activity on common agricultural pathogenic bacteria; the active protein extracted from pumpkin seeds has N-glycosidase activity and has a strong inhibition effect on proliferation of human melanoma cells. These studies indicate that pumpkin seed protein has certain physiological activity.
Although the pumpkin seed protein has high nutritive value and other application, the pumpkin seed protein is not developed and utilized enough in the aspects of health food, medicine and the like. Proteins are of increasing interest as important nutrients for the health of the intestinal tract. Intestinal flora can participate in protein metabolism of an organism, food proteins can influence the composition and balance of the intestinal flora, and changes of the intestinal flora influence the utilization of the protein by the organism. If the pumpkin seed protein with the function of regulating the intestinal health is extracted, the application range of the pumpkin seed protein can be widened, the multifunctional peptide resource is enriched, and the pumpkin seed protein is also important for improving the intestinal health and/or preventing chronic diseases and complications.
Disclosure of Invention
Aiming at the defects of the prior art, the invention provides the pumpkin seed protein composition capable of promoting the proliferation of intestinal probiotics (beneficial bacteria), reducing pathogenic bacteria (harmful bacteria), effectively reducing the pH value of a culture medium containing lactobacillus acidophilus, streptococcus thermophilus and bifidobacterium, promoting the production of short-chain fatty acid, inhibiting the growth of putrefying bacteria, promoting the gastrointestinal peristalsis and the growth of the probiotics and regulating the health of the intestinal tract and application thereof. The pumpkin seed protein can be added into various products or be compatible with other components according to different requirements; the protein component is easy to use and safe in composition, and the pumpkin seed protein can be any one or more of separated pumpkin seed protein, concentrated pumpkin seed protein or hydrolyzed pumpkin seed protein.
In one aspect, the invention provides a method of increasing the level of a first intestinal microbiota in a subject, comprising: administering to the subject a composition comprising pumpkin seed protein or isolated protein, hydrolyzed protein, and concentrated protein; the composition is effective to increase the level of a first gut microbiota in the subject; the first intestinal microbiota is selected from one or more of the following: lactobacillus acidophilus, streptococcus thermophilus, bifidobacterium longum and bifidobacterium lactis.
In some embodiments, the above method further comprises: reducing the level of E.coli in the subject.
In some embodiments, the first intestinal microbiota is intestinal probiotics.
In some embodiments, the composition is formulated as a nutritional supplement, food, beverage, animal feed, or pharmaceutical.
In some embodiments, the composition is prepared as a solid formulation or a liquid formulation.
In some embodiments, the composition is in the form of a suppository, tablet, pill, granule, powder, film, capsule, beverage, aerosol, spirit, tincture, tonic, liquid suspension, or syrup.
In some embodiments, the composition is administered to the subject at a dose of 0.1 to 500g, preferably 1 to 400g,2 to 300g,3 to 200g,5 to 100g per day. Alternatively, the composition may be administered to the subject at a dose of 0.1-10g/kg,0.5-5g/kg,1-3g/kg per day.
In another aspect, the invention provides a use of a composition comprising pumpkin seed protein or isolated protein, hydrolyzed protein, concentrated protein thereof in the manufacture of a nutritional supplement, food, beverage, animal feed, or medicament for increasing the level of a first intestinal microbiota in a subject, the first intestinal microbiota selected from one or more of the following: lactobacillus acidophilus, streptococcus thermophilus, bifidobacterium longum and bifidobacterium lactis. Preferably, the first intestinal microbiota is an intestinal probiotic.
In some embodiments, the above uses further comprise: reducing the level of E.coli in the subject.
In some embodiments, the composition is administered to the subject at a dose of 0.1 to 500g, preferably 1 to 400g,2 to 300g,3 to 200g,5 to 100g per day; the composition is effective to increase the level of the first intestinal microbiota in the subject. Alternatively, the composition may be administered to the subject at a dose of 0.1-10g/kg,0.5-5g/kg,1-3g/kg per day.
In some embodiments, the composition is prepared as a solid formulation or a liquid formulation.
In some embodiments, the composition is in the form of a suppository, tablet, pill, granule, powder, film, capsule, beverage, aerosol, spirit, tincture, tonic, liquid suspension, or syrup.
The pumpkin seed protein is easy to be directly absorbed by intestinal tracts, can promote the proliferation of intestinal probiotics, reduce the quantity of intestinal pathogens, effectively reduce the pH value of a culture medium containing lactobacillus acidophilus, streptococcus thermophilus and bifidobacterium, and promote the production of short-chain fatty acid, thereby regulating the health of the intestinal tracts and/or the whole health; meanwhile, the novel functions and the nutrition characteristics of the pumpkin seed protein are discovered, and the added value of the pumpkin seed protein utilization is improved.
Drawings
FIG. 1A is a graph showing the growth of Lactobacillus acidophilus and Streptococcus thermophilus in the corresponding media with or without the addition of pumpkin seed protein.
FIG. 1B is a graph of the growth of two bifidobacteria in the corresponding medium with or without the addition of pumpkin seed protein.
FIG. 2 is a graph comparing colony log values of E.coli.
FIG. 3 is a graph showing the comparison of colony log values of Lactobacillus acidophilus, streptococcus thermophilus, bifidobacterium longum and Bifidobacterium lactis.
Detailed Description
Reference will now be made in detail to the preferred embodiments of the present invention, examples of which are further described. While the invention will be described in conjunction with the preferred embodiments, it will be understood that they are not intended to limit the invention to these embodiments. On the contrary, the invention is intended to cover alternatives, modifications and equivalents, which may be included within the spirit and scope of the invention as defined by the appended claims. Furthermore, in the detailed description of the present invention, numerous specific details are set forth in order to provide a thorough understanding of the present invention. It will be apparent, however, to one skilled in the art that the present invention may be practiced without these specific details. In other instances, well-known methods, procedures, components, and other features have not been described in detail so as not to unnecessarily obscure aspects of the present invention.
As used herein, the term "or" is intended to include "and" or ". In other words, the term "or" may also be replaced with "and/or".
As used herein, the singular forms "a," "an," and "the" are intended to include the plural forms as well, unless the context clearly indicates otherwise.
As used herein, the terms "comprises" or "comprising" or variations thereof mean the following, wherein the term is used in its non-limiting sense to refer to items following the inclusion of the word, but not to exclude items not specifically mentioned. It also includes the more restrictive verbs 'consisting essentially of … …' and 'consisting of … …'.
As used herein, the terms "subject" or "individual" are used interchangeably to refer to any subject to which the methods and compositions of the present disclosure may be applied or administered. The subject is likely to have a disease or disorder, but the subject need not be ill to benefit from the methods and compositions of the present disclosure. The subject may need to improve his or her intestinal and/or overall health, but the subject may also have an overall healthy intestinal tract and wish to maintain or further improve his or her intestinal and/or overall health. Thus, any subject may take the disclosed compositions or be the recipient of the disclosed methods. Herein, the term "subject" refers to animals (e.g., birds, reptiles, and mammals). In certain embodiments, the subject can be a mammal including a non-primate (e.g., camel, donkey, zebra, cow, horse, cat, dog, rat, and mouse) and a primate (e.g., monkey, chimpanzee, human). In certain embodiments, the subject may be a non-human mammal. In other embodiments, the subject may be a human.
As used herein, the term "administering" refers to the process of delivering the disclosed compositions or active ingredients to a subject. The compositions of the present invention may be administered in a variety of ways to exert the desired effect, including oral, intragastric and parenteral (i.e. intravenous and intraarterial, as well as other suitable parenteral routes), and the like.
As used herein, the term "protein" is defined as a native protein structure or a denatured protein structure or fragment thereof when describing protein concentration, protein molecular weight distribution, protein solubility, and protein amino acid content; it should be construed broadly and includes intact proteins, polypeptides, oligopeptides, amino acids, and mixtures thereof. "hydrolyzed protein (protein hydrolysate)" refers to a protein that is broken down into shorter peptide fragments and amino acids by partial or complete acidolysis or enzymolysis. "protein isolate" refers to proteinaceous material obtained from natural sources and/or modified natural sources upon removal of at least a portion (or majority) of one or more (or substantial portions) of polysaccharides, soluble carbohydrates, ash, and other minor components. "concentrating protein (protein concentrate)" refers to a proteinaceous material obtained from a natural source and/or modified natural source upon removal of at least a portion (or majority) of one or more (or substantial portions) of carbohydrates, lipids, ash, and other minor components.
As used herein, the term "effective amount" refers to the amount required to achieve the effect as taught herein. Effective amounts herein include, but are not limited to, an amount necessary to increase intestinal probiotics in a subject; and/or reducing the amount of gut pathogenic bacteria in a subject; and/or an amount necessary to improve intestinal health and/or overall health. According to the present disclosure, a suitable single dose size is a dose that is capable of achieving the above-described effects when administered one or more times over a suitable period of time.
As used herein, the term "pharmaceutically acceptable" refers to those compositions or agents, materials or combinations of compositions and/or dosage forms thereof that are pharmaceutically, physiologically, dietetically and/or nutritionally acceptable, suitable for contact with human and animal tissue, compatible with other ingredients of the composition, without undue toxicity, irritation, allergic response, or other problem or complication, commensurate with a reasonable benefit/risk ratio, within the scope of sound medical judgment.
The present application finds that administration of pumpkin seed protein can significantly increase the level of the first intestinal microbiota in a subject while reducing the level of escherichia coli in the subject. To this end, the present invention and embodiments relate to methods and compositions using "pumpkin seed protein-containing" compositions and/or "pumpkin seed protein-enhanced" compositions, wherein the pumpkin seed protein-containing compositions include any composition having pumpkin seed protein or isolated, hydrolyzed, concentrated proteins thereof.
The method of the invention comprises administering at least 0.1g, typically 0.1-500g,1-400g, preferably 2-300g,3-200g,5-100g of the composition comprising pumpkin seed protein per day, depending on the specific formulation and form. The amount to be administered may also vary from 0.1 to 10g/kg, from 0.5 to 5g/kg, from 1 to 3g/kg of subject body weight per day, depending on factors such as the sensitivity, age, sex and body weight of the subject, specific response, etc. One or more doses may be administered once or more times daily or at a suitable frequency over any period of time. For example, an effective dose may be administered daily for one, several, multiple, or indefinitely daily.
The pumpkin seed protein-containing composition of the present invention may be formulated as a nutritional supplement or dietary supplement, (medical) food, animal feed or pharmaceutical composition, in liquid or solid form, and may also optionally include a nutritionally or pharmaceutically acceptable carrier. For example, in solid form, the composition may be formulated as a snack bar, yogurt, lozenge, tablet or capsule. On the other hand, when in liquid form, the composition may be formulated as a tincture, a soft gel capsule, a liquid capsule, a syrup, a carbonated beverage, a brew (e.g., coffee or tea), a juice, an energy beverage, a sport beverage, or a flavored water. While nutritional and pharmaceutical compositions for human use are particularly contemplated, it is to be understood that the pumpkin seed protein-containing compositions and formulations may also be used for veterinary purposes (e.g., animal feed for domestic companion animals ("pets") or animal feed for farm animals. In other contemplated aspects, the pumpkin seed protein-containing compositions may also be provided in bulk product form (e.g., in amounts of 100g or greater, 1000g or greater, or 10kg or greater) for use in the production of nutritional supplements, (medical) foods, animal feeds, or pharmaceuticals.
In order to further enhance the intestinal health of the subject, contemplated methods of administering the pumpkin seed protein-containing composition include administering at least one probiotic microorganism either simultaneously with or subsequent to administration of the pumpkin seed protein-containing composition. In addition, the composition may be combined with one or two prebiotics of Arabinoxylan (AX), arabinoxylan oligosaccharides (AXOS), xylo-oligosaccharides (XOS), fructo-oligosaccharides (FOS), galacto-oligosaccharides (GOS), inulin and/or pectin.
The pumpkin seed protein-containing composition of the present invention may be combined with health additives to increase the breadth of health benefits. The health additives may be added in any combination with the composition containing the pumpkin seed protein, depending on the form of the composition and consideration of desired health effects and product costs. Exemplary additives that may be combined with the pumpkin seed protein-containing composition include superoxide dismutase (SOD), compositions comprising activators of SOD, foods comprising bioavailable SOD or extracts thereof (e.g., germinated wheat, wheat straw, encapsulated (lipid and/or protein encapsulated) cantaloupe, rye, barley straw, broccoli sprouts, kale, brussels sprouts, and curcumin (e.g., turmeric)), copper iodide (CuI), selenium (Se), fulvic acid, foods comprising fulvic acid or extracts thereof (e.g., potato, radish, beet, carrot, rhizome vegetables, blackstrap molasses, and himalayan), coenzyme Q10 (ubiquinone), or pyrroloquinoline quinone (PQQ).
The following examples are illustrative of selected embodiments of the invention and are not meant to limit the scope of the invention.
Example 1
Inoculating each strain with 2% of inoculating amount into each culture medium with or without adding semen Cucurbitae protein or its isolated protein, hydrolyzed protein, and concentrated protein: lactobacillus acidophilus (l.acid) 563 was cultured in MRS liquid medium at 37 ℃ with standing; streptococcus thermophilus (S.thermophilus) 176 was grown on Eliker medium at 42℃in a stationary manner; bifidobacterium longum BB536 and bifidobacterium lactis BB12 were anaerobically cultured in MRS medium (MRS medium containing 0.05% l-cysteine hydrochloride) at 37 ℃. The culture was carried out until the logarithmic phase was reached at a certain time, and then the pH values of the two fermentation broths of each group were measured, and viable count was carried out, and the results are shown in Table 1.
TABLE 1
As shown in table 1, the pH of the proteome was lowered compared to the control group, indicating that the pumpkin seed protein was effective in lowering the pH of the culture medium containing lactobacillus acidophilus, streptococcus thermophilus, bifidobacterium longum and bifidobacterium lactis, and it was seen that the pumpkin seed protein promoted the production of short chain fatty acids, thereby inhibiting the growth of spoilage bacteria, promoting gastrointestinal motility and probiotic growth; the number of viable bacteria of the protein group is increased, which indicates that the pumpkin seed protein can effectively improve the number of viable bacteria of lactobacillus acidophilus, streptococcus thermophilus, bifidobacterium longum and bifidobacterium lactis.
In addition, the OD value of the two bifidobacteria at 600nm was measured by sampling every 2 hours within 0 to 30 hours after culturing lactobacillus acidophilus 563 and streptococcus thermophilus 176. The growth curves of the probiotics were plotted as a function of OD values over time, and the results are shown in fig. 1A and 1B.
All experiments were performed in 3 replicates, and the results were expressed as mean ± standard deviation.
FIG. 1A is a graph showing the growth of Lactobacillus acidophilus 563 and Streptococcus thermophilus 176 in corresponding media with or without the addition of pumpkin seed protein or its isolated protein, hydrolyzed protein, and concentrated protein. Fig. 1B is a graph of growth of bifidobacterium longum BB536 and bifidobacterium lactis BB12 in the respective media with or without the addition of pumpkin seed protein or isolated protein, hydrolyzed protein, concentrated protein thereof. As shown in fig. 1A, the OD values of both lactobacillus acidophilus 563 and streptococcus thermophilus 176 were changed faster and maintained at higher levels when cultured with the addition of pumpkin seed protein than when not. As shown in fig. 1B, when culturing with the addition of pumpkin seed protein, the OD value of bifidobacterium longum BB536 changed faster than when culturing without the addition of pumpkin seed protein, and the OD value of the cultured group without the addition of pumpkin seed protein had tended to be unchanged at 26 hours, while the cultured group with the addition of pumpkin seed protein had a tendency to increase; the OD values of bifidobacterium lactis BB12 changed faster and remained at higher levels earlier than without the addition of pumpkin seed protein. The pumpkin seed protein is shown to be effective in promoting proliferation of lactobacillus acidophilus, streptococcus thermophilus, bifidobacterium longum and bifidobacterium lactis.
Example 2
SPF-class male SD rats 20 were divided into a blank group and a pumpkin seed protein group, and were fed with normal feed, distilled water was drunk, and environmental parameters: the temperature (23+ -1) deg.C and the relative humidity (60+ -5)%, and 12 hours. The blank group is fed with normal feed and distilled water with equal volume, and the pumpkin seed protein group is fed with pumpkin seed protein besides the normal feed. The pumpkin seed protein group is administered with about 1-3g/kg of pumpkin seed protein or its isolated protein, hydrolyzed protein and concentrated protein every day.
After 30 days of feeding, two groups of mouse faeces were collected for intestinal flora cultivation and analysis. Collecting fresh faecal balls at the tail end of the rectum of the rat manually, and diluting to 10 -9 The culture was performed under appropriate conditions by dibbling onto various media. After culturing, the intestinal flora 16S rDNA is subjected to high-throughput sequencing and metabonomics analysis to form colonyBacterial count in units lg (CFU/g), colony changes were analyzed in comparison, and the results are shown in fig. 2 and 3.
FIG. 2 is a graph comparing colony log values of E.coli in a blank group and a pumpkin seed protein treated group. As shown in FIG. 2, the E.coli in the pumpkin seed protein group was reduced by 12.07% compared to the blank group, indicating that the pumpkin seed protein can effectively reduce the E.coli content.
FIG. 3 is a graph showing the comparison of colony log values of Lactobacillus acidophilus, streptococcus thermophilus, bifidobacterium longum and Bifidobacterium lactis in the blank group and the pumpkin seed protein treated group. As shown in fig. 3, lactobacillus acidophilus, streptococcus thermophilus, bifidobacterium longum and bifidobacterium lactis were increased by 4.97%, 11.66%, 5.65% and 5.58% respectively in the pumpkin seed protein group compared to the blank group, indicating that the pumpkin seed protein can effectively promote proliferation of lactobacillus acidophilus, streptococcus thermophilus, bifidobacterium longum and bifidobacterium lactis in vivo.
In the invention, after the pumpkin seed protein is treated, the content of other intestinal probiotics can be increased, such as lactobacillus rhamnosus, bifidobacterium adolescentis, lactobacillus bulgaricus and the like; reducing the content of other intestinal pathogens such as Staphylococcus aureus, pseudomonas aeruginosa, salmonella, etc. This allows the level of intestinal microbiota to be maintained and/or restored to near normal levels, which is highly beneficial for maintaining intestinal health and/or overall health.
The pumpkin seed protein disclosed by the invention can promote the proliferation of intestinal probiotics, reduce the number of pathogenic bacteria, effectively reduce the pH value of a culture medium containing lactobacillus acidophilus, streptococcus thermophilus and bifidobacterium, promote the production of short-chain fatty acid, further regulate the health of intestinal tracts, and can be compatible with different components according to different requirements, so that the health and/or the overall health of the intestinal tracts can be regulated while the requirements of vegetarian are met; lays a foundation for the production and application of various products such as medicines, health products and the like by using pumpkin seed protein and corresponding polypeptide components in future development and utilization.
The foregoing is only illustrative of the preferred embodiments of the invention and is not intended to be limiting, since various changes, modifications, substitutions and alterations can be made herein by those skilled in the art without departing from the spirit and scope of the invention as defined by the appended claims and their equivalents.

Claims (12)

1. A method of increasing the level of a first intestinal microbiota in a subject, the method comprising: administering to the subject a composition comprising pumpkin seed protein or isolated protein, hydrolyzed protein, and concentrated protein thereof; the composition is effective to increase the level of the first intestinal microbiota in the subject; the first intestinal microbiota is selected from one or more of the following: lactobacillus acidophilus, streptococcus thermophilus, bifidobacterium longum and bifidobacterium lactis.
2. The method according to claim 1, wherein the method further comprises: reducing the level of escherichia coli in the subject.
3. The method according to claim 1 or 2, wherein the first intestinal microbiota is an intestinal probiotic.
4. The method of claim 1 or 2, wherein the composition is formulated as a nutritional supplement, food, beverage, animal feed, or pharmaceutical.
5. The method according to claim 1 or 2, wherein the composition is prepared as a solid formulation or a liquid formulation.
6. The method of claim 1 or 2, wherein the composition is in the form of a suppository, tablet, pill, granule, powder, film, capsule, beverage, aerosol, spirit, tincture, tonic, liquid suspension, or syrup.
7. The method of claim 1 or 2, wherein the composition is administered to the subject at a dose of 0.1-500g per day.
8. Use of a composition comprising pumpkin seed protein or isolated protein, hydrolyzed protein, concentrated protein thereof in the manufacture of a nutritional supplement, food, beverage, animal feed, or medicament for increasing the level of a first intestinal microbiota in a subject, characterized in that the first intestinal microbiota is selected from one or more of the following: lactobacillus acidophilus, streptococcus thermophilus, bifidobacterium longum and bifidobacterium lactis.
9. The use according to claim 8, further comprising: reducing the level of escherichia coli in the subject.
10. The use according to claim 8 or 9, wherein the composition is administered to the subject at a dose of 0.1-500g per day; the composition is effective to increase the level of the first intestinal microbiota in the subject.
11. Use according to claim 8 or 9, wherein the composition is prepared as a solid or liquid formulation.
12. The use according to claim 8 or 9, wherein the composition is in the form of a suppository, tablet, pill, granule, powder, film, capsule, beverage, aerosol, spirit, tincture, tonic, liquid suspension or syrup.
CN202211114142.1A 2022-09-14 2022-09-14 Pumpkin seed protein composition and application thereof Pending CN117731007A (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
CN202211114142.1A CN117731007A (en) 2022-09-14 2022-09-14 Pumpkin seed protein composition and application thereof
PCT/CN2023/118501 WO2024055983A1 (en) 2022-09-14 2023-09-13 Composition of pumpkin seed protein and use thereof

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN202211114142.1A CN117731007A (en) 2022-09-14 2022-09-14 Pumpkin seed protein composition and application thereof

Publications (1)

Publication Number Publication Date
CN117731007A true CN117731007A (en) 2024-03-22

Family

ID=90274289

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202211114142.1A Pending CN117731007A (en) 2022-09-14 2022-09-14 Pumpkin seed protein composition and application thereof

Country Status (2)

Country Link
CN (1) CN117731007A (en)
WO (1) WO2024055983A1 (en)

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105520151B (en) * 2016-01-26 2019-01-08 青岛森淼实业有限公司 Fruits and vegetables albumen powder nutritional supplement and preparation method thereof
CN106820156A (en) * 2017-02-17 2017-06-13 福建康是美生物科技有限公司 A kind of probiotic composition of regulating intestinal canal flora health
CN108310238A (en) * 2018-03-15 2018-07-24 武汉虹辰远荣生物制品有限公司 A kind of probiotic composition of prevention diarrhea
CN111019990B (en) * 2018-10-09 2023-09-29 杏辉天力（杭州）药业有限公司 Pumpkin seed peptide powder and preparation method and application thereof
CN109662311A (en) * 2018-12-13 2019-04-23 武汉森澜生物科技有限公司 Ferment and its preparation method and application with function of relaxing bowel

Also Published As

Publication number Publication date
WO2024055983A1 (en) 2024-03-21

Similar Documents

Publication Publication Date Title
US9101651B2 (en) Lactobacillus rhamnosus and weight control
US8318151B2 (en) Lactobacillus rhamnosus NCC4007, a probiotic mixture and weight control
JP5923238B2 (en) Vagus nerve activator
CN109430666A (en) A kind of Freeze-dry Powder of Probioctics solid beverage
US20080102061A1 (en) Use hydrolyzed medium containing microorganisms medicinally
Arshad et al. Lactobacilli as probiotics and their isolation from different sources
KR101992537B1 (en) Novel Lactobacillus sakei and compositions comprising the same
JP2022522300A (en) A composition for the prevention, amelioration or treatment of obesity or fatty liver disease containing Leuconostoc citreum WIKIM0104.
JP7296454B2 (en) Combinations of probiotics for the treatment of inflammation-related gastrointestinal disorders
JP5592640B2 (en) Antistress agent containing lactic acid bacteria fermented royal jelly, method for producing the same, hypothalamus-pituitary-adrenocortical activity inhibitor, and sympathetic-adrenal medullary activity inhibitor
CN111713555A (en) Probiotic fermented camel milk capable of relaxing bowels and preparation method thereof
EP3479836B1 (en) Cartilage regeneration facilitating composition
KR102244732B1 (en) Probiotic acetic acid bacteria Acetobacter pasteurianus MGLV and its immunomodulatory effect
US20130004475A1 (en) Agent for increasing bifidobacteria and reducing the decrease of bifidobacteria in large intestine
CN117731007A (en) Pumpkin seed protein composition and application thereof
CN102742654A (en) Beautification probiotic ewe milk tablet and preparation method thereof
JP2022530384A (en) Microbial compositions and methods for higher tolerance and extended shelf life
WO2024055976A1 (en) Composition of sunflower seed protein and use thereof
KR102606636B1 (en) Bacillus velezensis having the effect of preventing or improving for sarcopenia and uses thereof
CN112840017B (en) Lactic acid bacteria, blood iron increasing agent and anemia improving agent
US20220339213A1 (en) Probiotic compositions and methods of use thereof
CN110973630A (en) Composition for resisting intestinal aging and application thereof
EP3839042A1 (en) Lactic acid bacterium, agent for increasing blood iron, and agent for ameliorating anemia
Mc Donagh et al. Milk and dairy products for better human health
CN117794557A (en) Metaplasia element

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination